Johns Hopkins Medicine International shared a post on LinkedIn:

“Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — improved long-term survival overall compared with chemotherapy alone, according to a landmark study from JohnsHopkins.

‘Just three doses of immunotherapy and chemotherapy showing a survival advantage is a big step forward for patients,’ says Julie Brahmer, M.D., director of thoracic oncology at the Johns Hopkins Kimmel Cancer Center.”

Read “Five-Year Analysis Shows Immunotherapy Plus Chemotherapy Before Lung Cancer Surgery Significantly Improves Long-Term Survival”.

More posts about Johns Hopkins Medicine International on OncoDaily.

Immunotherapy Plus Chemotherapy Before Surgery Improves Long-Term Survival in NSCLC – Johns Hopkins Medicine International

“Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — improved long-term survival overall compared with chemotherapy alone, according to a landmark study from JohnsHopkins.

‘Just three doses of immunotherapy and chemotherapy showing a survival advantage is a big step forward for patients,’ says Julie Brahmer, M.D., director of thoracic oncology at the Johns Hopkins Kimmel Cancer Center.”